Guardant Health, Inc. announced major new features for the Guardant360 Liquid test, significantly expanding its biomarker identification and cancer subtyping capabilities. These advancements aim to help oncologists identify optimal treatment plans for patients.
The expanded applications are enabled by the multiomic profiling capabilities of the Guardant Infinity smart liquid biopsy platform and its AI learning engine. This technology analyzes large patient data sets to identify patterns and refine predictions, providing vital details about a tumor's phenotype and biological behavior from a blood sample.
Helmy Eltoukhy, Guardant Health chairman and co-CEO, highlighted that this allows healthcare providers to make smarter treatment decisions, even when tumor tissue is unavailable. The novel blood-based approach to comprehensive molecular profiling offers immense potential for future applications in cancer, with test results available within seven days.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.